These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 9366029

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Transfer of escitalopram and its metabolite demethylescitalopram into breastmilk.
    Rampono J, Hackett LP, Kristensen JH, Kohan R, Page-Sharp M, Ilett KF.
    Br J Clin Pharmacol; 2006 Sep; 62(3):316-22. PubMed ID: 16934048
    [Abstract] [Full Text] [Related]

  • 23. Effects of grapefruit juice and smoking on verapamil concentrations in steady state.
    Fuhr U, Müller-Peltzer H, Kern R, Lopez-Rojas P, Jünemann M, Harder S, Staib AH.
    Eur J Clin Pharmacol; 2002 Apr; 58(1):45-53. PubMed ID: 11956673
    [Abstract] [Full Text] [Related]

  • 24. Enantioselective analysis of citalopram and demethylcitalopram in human and rat plasma by chiral LC-MS/MS: application to pharmacokinetics.
    Rocha A, Marques MP, Coelho EB, Lanchote VL.
    Chirality; 2007 Nov; 19(10):793-801. PubMed ID: 17722014
    [Abstract] [Full Text] [Related]

  • 25. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
    Lemma GL, Wang Z, Hamman MA, Zaheer NA, Gorski JC, Hall SD.
    Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446
    [Abstract] [Full Text] [Related]

  • 26. In vitro release and stereoselective disposition of flurbiprofen loaded to poly(D,L-lactide- co-glycolide) nanoparticles in rats.
    Radwan MA, Aboul-Enein HY.
    Chirality; 2004 Feb; 16(2):119-25. PubMed ID: 14712475
    [Abstract] [Full Text] [Related]

  • 27. Escitalopram, but not its major metabolites, exhibits antiplatelet activity in humans.
    Atar D, Malinin A, Takserman A, Pokov A, van Zyl L, Tanguay JF, Lesperance F, Serebruany V.
    J Clin Psychopharmacol; 2006 Apr; 26(2):172-7. PubMed ID: 16633147
    [Abstract] [Full Text] [Related]

  • 28. Development and application of a chiral high performance liquid chromatography assay for pharmacokinetic studies of methadone.
    Boulton DW, Devane CL.
    Chirality; 2000 Oct; 12(9):681-7. PubMed ID: 10984743
    [Abstract] [Full Text] [Related]

  • 29. Determination of citalopram and escitalopram together with their active main metabolites desmethyl(es-)citalopram in human serum by column-switching high performance liquid chromatography (HPLC) and spectrophotometric detection.
    Greiner C, Hiemke C, Bader W, Haen E.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Apr 01; 848(2):391-4. PubMed ID: 17112793
    [Abstract] [Full Text] [Related]

  • 30. Formation of solid solutions between racemic and enantiomeric citalopram oxalate.
    de Diego HL, Bond AD, Dancer RJ.
    Chirality; 2011 May 01; 23(5):408-16. PubMed ID: 21472783
    [Abstract] [Full Text] [Related]

  • 31. Stereoselective pharmacokinetic analysis of tramadol and its main phase I metabolites in healthy subjects after intravenous and oral administration of racemic tramadol.
    García Quetglas E, Azanza JR, Cardenas E, Sádaba B, Campanero MA.
    Biopharm Drug Dispos; 2007 Jan 01; 28(1):19-33. PubMed ID: 17061296
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
    Cao YJ, Smith PF, Wire MB, Lou Y, Lancaster CT, Causon RC, Bigelow GE, Martinez E, Fuchs EJ, Radebaugh C, McCabe S, Hendrix CW.
    Pharmacotherapy; 2008 Jul 01; 28(7):863-74. PubMed ID: 18576901
    [Abstract] [Full Text] [Related]

  • 34. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997.
    Reis M, Lundmark J, Bengtsson F.
    Ther Drug Monit; 2003 Apr 01; 25(2):183-91. PubMed ID: 12657912
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Pharmacokinetics of thiamylal enantiomers in humans.
    Sueyasu M, Ikeda T, Taniyama T, Futugami K, Kataoka Y, Oishi R.
    Int J Clin Pharmacol Ther; 1997 Mar 01; 35(3):128-32. PubMed ID: 9089003
    [Abstract] [Full Text] [Related]

  • 38. In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats.
    Kugelberg FC, Apelqvist G, Carlsson B, Ahlner J, Bengtsson F.
    Br J Pharmacol; 2001 Apr 01; 132(8):1683-90. PubMed ID: 11309239
    [Abstract] [Full Text] [Related]

  • 39. Plasma levels of citalopram enantiomers and metabolites in elderly patients.
    Foglia JP, Pollock BG, Kirshner MA, Rosen J, Sweet R, Mulsant B.
    Psychopharmacol Bull; 1997 Apr 01; 33(1):109-12. PubMed ID: 9133760
    [Abstract] [Full Text] [Related]

  • 40. Solid-phase extraction with end-capped C2 columns for the routine measurement of racemic citalopram and metabolites in plasma by high-performance liquid chromatography.
    Carlsson B, Norlander B.
    J Chromatogr B Biomed Sci Appl; 1997 Nov 21; 702(1-2):234-9. PubMed ID: 9449577
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.